Hyperhomocysteinemia, atherosclerosis and thrombosis

Thrombosis and Haemostasis

Volumn 81, Issue 2, 1999, Pages 165-176

  Cattaneo, Marco ^a  

^a NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COBALAMIN; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; VITAMIN;

AMINO ACID BLOOD LEVEL; ARTERY THROMBOSIS; ATHEROSCLEROSIS; DISEASE SEVERITY; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; ENVIRONMENTAL FACTOR; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOEMBOLISM; THROMBOSIS; VEIN THROMBOSIS;

EID: 0033028586     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614438     Document Type: Review

References (156)

1. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1990; 1: 228-57.
2. Storch KJ, Wagne DA, Burke JF, Young VR. (1-13C; methyl-2H3)-Methionine kinetics in humans: methionine conservation and cysteine sparing. Am J Physiol 1990; 258: E790-E798.
3. Andersson A, Brattsröm L, Israelsson B, Isaksson A, Hamfelt A, Hultberg B. Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur J Clin Invest 1992; 22: 79-87.
4. Wouters MGAJ, Moorrees MTEC, van der Mooren MJ, Blom HJ, Boers GH, Schellekens LA, Thomas CM, Eskes TK. Plasma homocysteine and menopausal status. Eur J Clin Invest 1995; 25: 801-5.
5. Nygård O, Vollset SE, Refsum E, Stensvold I, Tverdal A, Nordrehaug JE, Ueland PM, Kvœle G. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995; 274: 1526-33.
6. Lussier-Cacan S, Xhignesse M, Piolot A, Selhub J, Davignon J, Genest J Jr. Plasma total homocysteine in healthy subjects: sex-specific relation with biological traits. Am J Clin Nutr 1996; 64: 587-93.
7. Selhub J, Jaques PF, Wilson PWF, Rush D, Rosenberg JH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693-8.
8. Nygård O, Refsum H, Ueland PM, Stensvold I, Nordrehaug J, Kvale G, Vollset SE. Coffee consumption and plasma total homocysteine: The Hordaland Homocysteine Study. Am J Clin Nutr 1997; 65: 136-43.
9. Cravo ML, Gloria LM, Selhub J, Nadeau MR, Camilo ME, Resende MP, Cardoso JN, Leitao CN, Mira FC. Hyperhomocysteinemia in chronic alcoholism: correlation with folate, vitamin B-12 and vitamin B-6 status. Am J Clin Nutr 1996; 63: 2204.
10. Naughton ER, Yap S, Mayne PD. Newborn screening for homocystinuria: Irish and world experience. Eur J Pediatr 1998; 157 (Suppl 2): S 84-7.
11. Mudd SH, Levy HL, Skovby F. Disorders of transulfuration. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR, Beaudet AL, Sly WS, Valle D, Stanbury JB, Wyngarden JB, Fredrickson DS (eds). New York: McGraw-Hill 1995; pp 1279-327.
12. Rozen R. Molecular genetics of methylenetetrahydrofolate reductase deficiency. J Inherit Metab Dis 1996; 19: 589-94.
13. 12 utilization. BioEssays 1990; 12: 3314.
14. Rees MW, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 1993; 71: 337-59.
15. Kang S-S, Zhou J, Wong PWK, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a termolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43: 414-21.
16. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Gen 1995; 10: 111-3.
17. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, Malinow MR, Willett WC, Rozen R. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996; 94: 2410-6.
18. Guttormsen AB, Ueland PM, Nesthus I, Nygård O, Schneede J, Vollset SE, Refsum H. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (>40 μmol/liter). The Hordaland Homocysteine Study. J Clin Invest 1996; 98: 2174-83.
19. Kang S-S. Critical points for determining moderate hyperhomocyst(e)inaemia. Eur J Clin Invest 1995; 25: 806-8.
20. Joosten E, van den Berg A, Riezler R, Naurath HJ, Lindenbaum J, Stabler SP, Allen RH. Metabolic evidence that deficiencies of vitamin B-12 (cobalamin), folate, and vitamin B-6 occur commonly in elderly people. Am J Clin Nutr 1993; 58: 468-76.
21. Selhub J, Jaques PF, Bostom AG, D'Agostino RB, Wilson PWF, Belanger AJ, O'Leary DH, Wolf PA, Schaeffer EJ, Rosenberg IH. Associanon between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332: 286-91.
22. McCully KS. Homocysteine and vascular disease. Nature Med 1996; 2: 386-9.
23. Ubbink JB, van der Merwe A, Delport R, Allen RH, Stabler SP, Riezler R, Vermaak WJH. The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest 1996; 98: 177-84.
24. Van der Mooren MJ, Wouters MG, Blom HJ, Schellekens LA, Eskes TK, Rolland R. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest 1994; 24: 733-6.
25. Giltay EJ, Hoogeveen EK, Elbers JMH, Gooren LJG, Asscheman H, Stehouwer CDA. Effects of sex steroids on plasma total homocysteine levels: a study in transsexual males and females. J Clin Endocrinol Metab 1998; 83: 550-3.
26. Anker G, Lonning PE, Ueland PM, Refsum H, Lien EA. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. Int J Cancer 1995; 60: 365-8.
27. Cattaneo M, Baglietto L, Zighetti ML, Bettega D, Robertson C, Costa A, Mannucci PM, Decensi A. Tamoxifen reduces plasma homocysteine levels in healthy women. Brit J Oncol 1998; 77: 2264-6.
28. Kang S-S, Wong PWK, Glickman PB, MacLeod CM, Jaffe IA. Protein-bound homocyst(e)ine in patients with rheumatoid arthritis undergoing D-penicillamine treatment. J Clin Pharmacol 1986; 26: 712-5.
29. Wiklund O, Fager G, Andersson A, Lundstam U, Masson P, Hultberg B, N-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein (a) levels. Atherosclerosis 1996; 119: 99-106.
30. Guba SC, Fink LM, Fonseca V. Hyperhomocysteinemia. An emerging and important risk factor for thromboembolic and cardiovascular disease. Am J Clin Pathol 1996; 105: 709-22.
31. Frantzen F, Faaren AL, Alfheim I, Nordhei AK. Enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem 1998; 44: 311-6.
32. Fowler B, Sardharwalla IB, Robins AJ. The detection of heterozygotes for homocystinuria by oral loading with L-methionine. Biochem J 1971; 122: pp 23-4.
33. Boers GHJ, Fowler B, Smals AGH, Trijbels FJM, Leermakers Al, Kleijer WJ, Kloppenborg PWC. Improved identification of heterozygotes for homocystinuria due to cystathionine synthase deficiency by the combination of methionine loading and enzyme determination in cultured fibroblasts. Hum Genet 1985; 69: 164-9.
34. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994; 14: 1080-3.
35. Fermo I, Viganò-D'Angelo S, Paroni R, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Int Med 1995; 123: 747-53.
36. Cattaneo M, Martinelli I, Mannucci PM. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 335: 974-5.
37. Graham IM, Daly LE, Refsum HM, Robinson K, Brattsröm LE, Ueland PM, Palma-Reis RJ, Boers GHJ, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witterman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Luis AC, Parrot-Roulaud FM, Soon Tan K, Higgins I, Garcon D, Medrano MJ, Candito M, Evans AE, Andria G. Plasma homocystine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775: 81.
38. Bostom AG, Roubenoff R, Dellaripa P, Nadeau MR, Sutherland P, Wilson PWF, Jaques PF, Selhub J, Rosenberg IH. Validation of abbreviated oral methionine-loading test. Clin Chem 1995; 41: 948-9.
39. Cattaneo M, Agati B, Lecchi A, Lombardi R, Zighetti ML, Taioli E, Mannucci PM. Comparison between the 2-hour and the 4-hour methionine loading test for the identification of subjects with methionine intolerance. Netherlands Journal of Medicine 1998; 52 (Suppl): S37.
40. Selhub J, Miller JW. The pathogenesis of homocysteinemia: interruption of the coordinate regulation by S-adenosylmethionine of the remethylation and transsulfuration of homocysteine. Am J Clin Nutr 1992; 55: 131-8.
41. Miller JW, Nadeau MR, Smith D, Selhub J. Vitamin B-6 deficiency vs folate deficiency: comparison of responses to methionine loading in rats. Am J Clin Nutr 1994; 59: 1033-9.
42. Cattaneo M, Tsai MY, Bucciarelli P, Taioli E, Zighetti ML, Bignell M, Mannucci PM. A common mutation in the methylene-teirahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (factor V:Q506). Arterioscler Thromb Vasc Biol 1997; 17: 1662-6.
43. Ubbink JB, Becker PJ, Vermaak WJ, Delport R. Results of B-vitamin supplementation study used in a prediction model to define a reference range for plasma homocysteine. Clin Chem 1995; 41: 1033-7.
44. Rasmussen K. Möller J, Lyngbak M, Pedersen AM, Dybkjaer L. Age-and gender-specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation. Clin Chem 1996; 42: 630-6.
45. Cattaneo M, Taioli E, Lecchi A, Lombardi R, Martinelli I, Zighetti ML, Mannucci PM. Effects of gender, genotype of methylene-tetrahydrofolate reductase and folate status on fasting levels and post-methionine load increments of homocysteine in plasma. Thromb Haemost 1997; 527 (Suppl).
46. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of atherosclerosis. Am J Pathol 1969; 56: 111-28.
47. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90: 1-11.
48. Refsum H, Ueland PM, Nygård O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Medicine 1998; 49: 31-62.
49. Wilcken DEL, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 1976; 57: 1079-82.
50. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease, probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
51. Robinson K, Arheart K, Refsum H, Brattström L, Boers G, Ueland P, Rubba P, Palma-Reis R, Meleady R, Daly L, Witteman J, Graham I, for the European COMAC Group. Low circulating folate and vitamin B6 concentrations. Risk factors for stroke, peripheral vascular disease, and coronary artery disease. Circulation, 1998; 97: 437-43.
52. Robinson K, Mayer EL, Miller DP, Green R, van Lente F, Gupta A, Kattke-Marchant K, Savon SR, Selhub J, Nissen SE, Kutner M, Topol EJ, Jacobsen DW. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995; 92: 2825-30.
53. Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR. Eckfeldt JH, Hess DL, Davi CE. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1998; 98: 204-10.
54. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis in Communities (ARIC) Study. Circulation 1993; 87: 1107-13.
55. Bots ML, Launer LJ, Lindemans J, Hofman A, Grobbee. Homocysteine, atherosclerosis and prevalent cardiovascular disease in the elderly: The Rotterdam Study. J Int Med 1997; 242: 339-47.
56. Konecki N, Malinow R, Tunick PA, Freedberg RS, Rosenzweig BP, Katz ES, Hess DL, Upson B, Leung B, Perez J, Kronzon I. Correlation between plasma homocyst(e)ine and aortic atherosclerosis. Am Heart J 1997; 133: 534-40.
57. Verhoef P, Kok FJ, Kruyssen DACM. Schouten EG, Witteman JC, Grobbe DE, Ueland PM, Refsum H. Plasma total homocysteine, B vitamins and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 989-95.
58. von Eckardstein A, Malinow MR, Upson B, Heinrich T, Schulte H, Schonfeld R, Kohler E, Assmann G. Effects of age, lipoproteins, and hemostatic parameters on the role of homocystinemia as a cardiovascular risk factor in men. Arterioscler Thromb 1994; 14: 460-4.
59. van den Berg M, Stehouwer CDA, Bierdrager E, Rauwerda JA. Plasma homocysteine and severity of atherosclerosis in young patients with lower-limb atherosclerotic disease. Arterioscler Thromb Vasc Biol 1996; 16: 165-71.
60. Taylor LM, DeFrang RD, Harris EJ, Porter JM. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg 1991; 13: 128-36.
61. Alfthan G, Pekkanen J, Jauhiainen M, Pitkaniemi J, Karvonen M, Tuomilehto T, Salonen JT, Ehnholm C. Relation of serum homocysteine and lipoprotein (a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106: 9-19.
62. Stehouwer CDA, Weijenberg MP, van den Berg M. Serum homocysteine and the five year risk of cardiovascular diseases, cancer and cognitive impairment in elderly men. In: Weijenberg M, ed. Prospective Studies on Coronary Heart Disease in the Elderly: the Role of Classical and New Risk Factors. Wageningen. The Netherlands: Grafisch Bedrijf Ponsen & Looijen B.V. 1996; 83-99.
63. Arnesen E, Refsum H, Bonan KH, Ueland PM, Forde OH, Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24: 704-9.
64. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in U.S. physicians. JAMA 1992; 268: 877-81.
65. 6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 1996; 15: 136-43.
66. Verhoef P, Hennekens CH, Allen RH, Stabler SP, Willett WC, Stampfer MJ. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. Am J Cardiol 1997; 79: 799-801.
67. Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willert WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994; 25: 1924-30.
68. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. The Lancet 1995; 346: 1395-8.
69. Evans RW, Shalen BJ, Hempel JD, Cutler JA, Kuller LH, for the MRFIT Research Group. Homocyst(e)ine and risk of cardiovascular disease in the multiple risk factor intervention trial. Arterioscler Thromb Vasc Biol 1997; 17: 1947-53.
70. Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. Homocysteine and ischemic heart disease. Results of a prospective study with implications regarding prevention. Arch Intern Med 1998; 158: 862-7.
71. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-6.
72. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996; 348: 1120-4.
73. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, Vigo P, Mayer EL, Selhub J, Kutner M, Jacobsen DW. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996; 94: 2743-8.
74. Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney International 1997; 52: 10-20.
75. Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J, Dworkin L, Rosenberg IH. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 1997; 17: 2554-8.
76. Moustapha A, Naso A. Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, Robinson K, Dennis VW. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998; 20: 138-41.
77. Gudnason V, Stansbie D, Scott J, Bowron A, Nicaud V, Humphries S, on behalf of the EARS group. C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentration in different European populations. Atherosclerosis 1998; 136: 347-54.
78. Alfthan G, Aro A, Gey KF. Plasma homocysteine and cardiovascular disease mortality. The Lancet 1997; 349: 397.
79. Donner MG, Klein GK, Mathes PB, Schandt P, Richter WO. Plasma total homocysteine levels in patients with early-onset coronary heart disease and low cardiovascular risk profile. Metabolism 1998; 47: 273-9.
80. Kluijtmans LAJ, van den Heuvel LPWJ, Boers GHJ, Frosst P, Stevens EMB, van Oost BA, den Heijer M, Trijbels FJM, Rozen R, Blom HJ. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41.
81. Mudd SH, Havlik R, Levy HL, McKusick VA, Feinleib M. A study of cardiovascular risk in heterozygotes for homocystinuria. Am J Hum Genet 1981; 33: 883-93.
82. de Valk HW, van Eeden MKG, Banga JD, van der Griend R, de Groot E, Haas FJ, Meuwissen OJ, Duran M, Smeitimk JA, Poll-The BT, de Kierk JB, Wittebol-Post D, Rolland MO. Evaluation of the presence of premature atherosclerosis in adults with heterozygosity for cystathionine-beta-synthase deficiency. Stroke 1996; 27: 1134-6.
83. Boers GHJ, Smals AGH, Tijbels FJM, Fowler B, Bakkeren JAJM, Schoonderwaldt HC, Klijer WJ, Kloppenborg PWC. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313: 709-15.
84. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-55.
85. Kluijtmans LAJ, Kastelein JJP, Lindemans J, Boers GHJ, Heil SG, Bruschke AVG, Jukema JW, van den Heuvel LPWJ, Trijbels FJM, Boerma GJM, Verheugt FWA, Willems F, Blom HJ. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1997; 96: 2573-7.
86. Brattström L. Common mutation in the methylenetetrahydrofolate reductase gene offers no support for mild hyperhomocysteinemia being a causal risk factor for cardiovascular disease. Circulation 1997; 96: 3805-6.
87. Tsai MY, Bignell M, Schwichtenberg K, Hanson NQ. High prevalence of a mutation in the cystathionine β-synthase gene. Am J Hum Genet 1996; 59: 1262-7.
88. Sperandeo MP, De Franchis R, Andria G, Sebastio G. A 68-bp insertion found in a homocystinuric patient is a common variant and is skipped by alternative splicing of the cystathionine β-synthase mRNA. Am J Hum Genet 1996; 59: 1391-3.
89. Kluijtmans LAJ, Boers GHJ, Trijbels FJM, van Lith-Zanders HMA, van den Heuvel LPWJ, Blom HJ. A common 844ins68 insertion variant in the cystathionine-β-synthase gene. Biochem Mol Med 1997; 62: 23-5.
90. Brattsröm L, Tasgborn L, Lagerstedt C, Israelsson B, Hultber B. Plasma homocysteine in venous thromboembolism. Haemostasis 1991; 21: 51-7.
91. Bienvenu T, Ankri A, Chadefaux B, Montalescot G, Kamoun P. Elevated total plasma homocysteine, a risk factor for thrombosis: relation to coagulation and fibrinolytic parameters. Thromb Res 1993; 70: 123-9.
92. den Hejier M, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Wijermans PW, Bos GMJ. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995; 345: 882-5.
93. den Heijer M, Koster T, Blom HJ, Bos GMJ, Briët E, Reitsma PH, Vanderbroucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-62.
94. Simioni P, Prandoni P, Burlina A, Tormene D, Sardella C, Ferrari V. Beneditti L, Girolami A. Hyperhomocysteinemia and deep-vein thrombosis. A case control study. 1996;76: 883-6.
95. Amundsen T, Ueland PM, Waage A. Plasma homocysteine levels in patients with deep venous thrombosis. Arterioscler Thromb Vasc Biol 1995; 15: 1321-3.
96. Martinelli I, Cattaneo M, Panzeri D, Taioli E, Mannucci PM. Risk factors for primary deep vein thrombosis of the upper extremities. Ann Intern Med 1997; 126: 707-11.
97. den Heijer M, Blom HJ, Gerrits WBJ, Rosendaal FR, Bos GMJ. Hyperhomocysteinemia and venous thrombosis: a quantitative review. Thromb Haemost 1997; 532 (Suppl).
98. Kluijtmans LAJ, Boers GHJ, Verbruggen B, Trijbels FJM, Novakova IRO, Blom HJ. Homozygous cystathionine β-synthase deficiency, combined with factor V Leiden or thermolabile methylenetetrahydrofolate reductase in the risk of venous thrombosis. Blood 1998; 91: 2015-8.
99. Mandel H, Brenner B, Berant M, Rosenberg N, Lanir N, Jakobs C, Fowler B, Seligsohn U. Coexistence of hereditary homocystinuria and factor V Leiden - effect on thrombosis. N Engl J Med 1996; 334: 763: 768.
100. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997; 95: 1777-82.
101. Cattaneo M, Zighetti ML, Turner RM, Thompson SG, Lowe GDO, Haverkate F, Bertina RM, Turpie AGG, Mannucci PM, and the ECAT DVT Study Group. Fasting plasma homocysteine levels do not predict the occurrence of deep-vein thrombosis after elective hip replacement surgery. Netherlands Journal of Medicine 1998; 52 (Suppl): S 21.
102. Cattaneo M, Monzani ML, Martinelli I, Falcon CR, Mannucci PM. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1998; 97: 295.
103. Eichinger S, Stümpfen A, Hirschl M, Blalonczyk C. Herkner K, Stain M, Schneider B, Pabinger I, Lechner K, Kyrle PA. Heperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998; 80: 566-9.
104. Arruda VR, von Zuben PM, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF, The mutation ALA677 VAL in the methylene-tetrahydrofolate reductase gene: a risk factor for arterial disease and venous thrombosis. Thromb Haemost 1997; 77: 818-21.
105. Trillot N, Preudhomme C, Alhenc-Gelas M, Gaveriaux V, Bauters A, Gandrille S, Aiach M. Jude B. Thermolabile methylene tetrahydrofolate reductase (MTHFR) does not modify the risk for venous thromboembolism in subjects with heterozygous factor V Leiden. Blood 1996; 10 (Suppl 1):284a.
106. Kluijtmans LAJ, den Heijer M, Reitsma PH, Heil SG, Blom HJ, Rosendaal FR. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost 1998; 79: 254-8.
107. Gaustadnes M, Larsen TB, Ingerslev J, Norgard-Petersen B, Madsen M, Bihl K, Rudiger N, Prevalence of the factor V Leiden mutation and the MTHFR C677T mutation in thrombophilic and healthy persons. Thromb Haemost 1997, 568 (Suppl) (Abstract).
108. Rintelen C, Pabinger I, Lechner K, Eichinger S, Kyrle PA, Mannhalter C. No evidence for an increased risk of venous thrombosis in patients with factor V Leiden by the homozygous mutation in the methylenetetrahydrofolate reductase gene. Thromb Haemost 1997; 569 (Suppl) (Abstract).
109. Salamor O, Dardik R, Zivelin A, Inbal A, Varon D, Martinowitz U, Mani A, Seligsohn U. Homozygous methylenetetrahydorofolate reductase thermolability (MTHFR-T) is an independent risk factor for idiopathic deep-vein thrombosis (DVT). Thromb Haemost 1997; 568-9 (Suppl) (Abstract).
110. De Stefano V, Chiusolo P, Paciaroni K, Casorelli I, Serra FG, Bizzi B, Leone G. Prevalence of factor V 1691G to A and methylenetetrahydrofolate reductase 677C to T mutated genes in patients with venous thrombosis. Thromb Haemost 1997; 569-70 (Suppl) (Abstract).
111. Margaglione M, D'Andrea G, d'Addedda M, Giuliani N, Cappucci G, Iannaccone L, Vecchione G, Grandone E, Brancaccio V, Di Minno G. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the prothrombin A20210 mutation. Thromb Haemost 1998; 79: 907-11.
112. Tosetto A, Missiaglia E, Frezzato M, Rodeghiero F. The VITA project: C677T mutation in the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism. Br J Haematol 1997; 97: 804-6.
113. Nedrebo BG, Ericsson UB, Nygård O, Refsum H, Ueland PM, Aakvaag A. Aanderud S, Lien EA. Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism 1998; 47: S9-93.
114. Cattaneo M, Vecchi M, Zighetti ML, Saibeni S, Martinelii I, Omodei P, Mannucci PM, de Franchis R. High prevalence of hyperhomocysteinemia in patients with inflammatory bowel disease: a pathogenic link with thromboembolic complications? Thromb Haemost 1998; 80: 542-5.
115. Roubenoff R, Dellaripa P, Nadeau MR, Abad LW, Muldoon BA, Selhub J, Rosenberg IH. Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis and Rheumatism 1997; 40: 718-22.
116. Refsum H, Wesenberg F, Ueland PM. Plasma homocysteine in children with acute lymphoblastic leukemia. Changes during a chemotherapeutic regimen including methotrexate. Cancer Res 1991; 51: 828-35.
117. Tonon G, Boyd K, Lecchi A, Lombardi R, Porcella A, Cattaneo M. Plasma homocysteine levels in 10 patients with polycythemia. Haemalologica 1997; 82: 343-4.
118. Hofman MA, Koll B, Zumbach MS, Borces V, Bierhaus A, Henkels M, Amiral J, Fiehn W, Ziegler R, Wahl P, Nawroth PP. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 1997: 20: 1880-6.
119. Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJ, Jakobs C, Bouter LM, Heine RJ, Stehouwer CD. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 1998; 18: 133-8.
120. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731-41.
121. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77: 1370-6.
122. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest 1986; 77: 1909-16.
123. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990; 75: 895-901.
124. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88: 1906-14.
125. Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 1992; 79: 2930-6.
126. Hajijar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993; 91: 2873-9.
127. Hajjar KA, Mauri L, Jacovina AT, Zhong F, Mirza UA, Padovan JC, Chait BT. Tissue plasminogen activator binding to annexin II tail domain. Direct modulation by homocysteine. J Biol Chem 1998; 273: 9987-93.
128. Stamler JS, Osborne JA, Javaki O, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308-18.
129. Welch GN, Upchurch GR Jr, Loscalzo J. Hyperhomocyst(e)inemia and atherothrombosis. Ann NY Acad Sci 1997; 811: 48-58.
130. Upchurch GR Jr, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keany JF Jr, Loscalzo J. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving gluiathione peroxidase. J Biol Chem 1997; 272: 17012-7.
131. Wang J, Dudman NPB, Wilcken DEL. Effects of homocysteine and related compounds on prostacyclin production by cultured human vascular endothelial cells. Thromb Haemost 1993; 70: 1047-52.
132. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 1993; 13: 1327-32.
133. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993; 92: 1381-6.
134. Broekman MJ, Haijar KA, Marcus AJ, Lev E, Islam N, Safier LB, Fliessbach J. Homocysteine inhibits ecto-ADPase activity of human umbilical vein endothelial cells. Blood 1994; 84 (Suppl 1): 77 (abstract).
135. Tsai J-C, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee ME. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369-73.
136. Majors A, Ehrhart LA, Pezacka EH. Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells. Arterioscler Thromb Vasc Biol 1997; 17: 2074-81.
137. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, Heistad DD. Vascular dysfunction in monkeys with diet-induced hyperhomocysteinemia. J Clin Invest 1996; 98: 24-9.
138. Cattaneo M, Martinelli I, Faioni E, Franchi F, Zighetti ML, Mannucci PM. Plasma levels of activated protein C in healthy subjects and patients with previous venous thromboembolism. Relationship with plasma homocysteine levels. Arterioscler Thromb Vasc Biol 1998; 18: 1371-5.
139. Coppola A, Cerbone AM, Guiotto G, Soriente L, Piemontino U, Rugiada F. Viganò D'Angelo S, Della Valle P, Mancini FP, Davì G, Di Minno G, Patrono C. A hypercoagulable state in homocystinuria due to homozygous cystathionine-β-synthase deficiency. Thromb Haemost 1997;528 (Suppl).
140. Di Minno G, Davì G, Margaglione M, Cirillo F, Grandone E, Ciabattoni G, Catalano I, Strisciuglio P, Andria G, Patrono C, Mancini M. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest 1993; 92: 1400-6.
141. Woo KS, Chook P, Lolin YI, Cheung ASP, Chan LT, Sun YY, Sanderson JE, Metreweli C, Celermajer DS. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol 1997; 96: 2542-4.
142. Chambers JC, McGregor A, Jean-Marie J, Kooner JS. Acute hyperhomocysleinaemia and endothelial dysfunction. Lancet 1998; 351: 36-7.
143. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997; 95: 1119-21.
144. Van der Mooren MJ, Wouters MG, Blom HJ, Schellekens LA, Eskes TK, Rolland R. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest 1994; 24: 733-6.
145. Anker G, Lonning PE, Ueland PM, Refsum H, Lien EA. Plasma levels of the atherogenic aminoacid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. Int J Cancer 1995; 60: 365-8.
146. Cattaneo M, Baglietto L, Zighetti ML, Bettega D, Robertson C, Costa A, Mannucci PM, Decensi A. Tamoxifen reduces plasma homocysteine levels in healthy women. Brit J Cancer 1998; 77: 2264-6.
147. McDonald CC, Alexander FE, White W, Forrest AP, Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial. Br Med J 1995; 311: 977-80.
148. Brattström L. Vitamins as homocysteine-lowering agents. J Nutr 1996; 126: 1276S-80S.
149. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ, Delport R, Potgeteter HC. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994; 124: 1927-33.
150. den Heijer M, Brewer IA, Bos GM, Blom HJ, van der Put NM, Spaans AP, Rosendaal FR, Thomas CM, Haak HL, Wijermans PW, Gerrits WB. Vitamin supplementation reduces blood homocysteine levels. A controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol 1998; 18: 356-61.
151. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Br Med J 1998; 316: 894-8.
152. Boston AG, Gohh RY, Beaulieau AJ, Nadeau MR, Hume AL, Jaques PF, Selhub J, Rosenberg IH. Treatment of hyperhomocysteinemia in renal transplant recipients. A randomized, placebo-controlled trial. Ann Intern Med 1997; 127: 1089-92.
153. Malinow MR, Duell PB, Hess DL, Anderson PH. Kruger WD, Phillipson BE. Gluckman RA, Block PC, Upson BM. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998; 338: 1009-15.
154. 6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998; 279: 359-64.
155. Tucker KL, Mahnken B, Wilson PWF, Jaques P, Selhub J. Folic acid fortification of the food supply. Potential benefits and risks for the elderly population. JAMA 1996; 276: 1879-5.
156. Rabkin SW, Sackett DL. Arterial thromboembolism. Epidemiology. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Philadelphia: J. B. Lippincott 1987; 1273-89.